RxDoctor Payments Data

Austrania Patterson, NP

Family · Baltimore, MDNPI 1417330820

Payments from drug & device makers

$560in general payments, 2019–2025

Across 28 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$126
  • Gilead$117
  • Novo Nordisk$106
  • GSK$38
  • Merck$33
  • Indivior Inc.$31
  • plus $108 from 5 others

What the payments were for

  • Food & beverage$560100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$560 in reported general payments places this provider in the 60th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$529
Medicare patients
38
Services billed
79

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala31$122,703
Trelegy ElliptaFluticasone/Umeclidin/Vilanter115$78,668
OzempicSemaglutide83$78,663
JardianceEmpagliflozin22$25,322
EliquisApixaban29$23,297
RybelsusSemaglutide16$22,649
Breo ElliptaFluticasone/Vilanterol52$20,247
OxycontinOxycodone Hcl14$19,926
SuboxoneBuprenorphine Hcl/Naloxone Hcl38$19,831
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl61$14,812
LinzessLinaclotide17$13,940
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,228
Albuterol Sulfate HfaAlbuterol Sulfate212$6,048
Arnuity ElliptaFluticasone Furoate22$4,884
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$117$122,70331 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$38$110,028203 claims
Novo NordiskOzempic, Rybelsus$106$101,31299 claims
Indivior Inc.Suboxone$31$19,83138 claims
AbbVieLinzess$126$13,94017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,843 family providers in Maryland.

Other family in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →